Carregant...
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis
BACKGROUND: Immune checkpoint inhibitors (ICIs) have become the standard of care for the first-line treatment of advanced non-small cell lung cancer patients (NSCLC), either as single agents or combined with chemotherapy. The evidence sustaining their role for poor performance status (ECOG PS ≥2) pa...
Guardat en:
| Publicat a: | Transl Lung Cancer Res |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AME Publishing Company
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8264315/ https://ncbi.nlm.nih.gov/pubmed/34295688 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-21-15 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|